Navigation Links
Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
Date:6/26/2008

Germantown, MD, June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.

Beta-catenin is one of the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer. The Beta-catenin pathway is upregulated in a large number of different cancer types, in particular colon cancer, where it has been estimated to be abnormally activated in at least 90 percent of cases.

"The biological complexity and the classically intractable nature of the beta-catenin protein have prevented this pathway from being effectively targeted by conventional drug discovery techniques, despite the efforts of numerous pharmaceutical companies," stated Kenneth Carter, Ph.D., President and CEO of Avalon Pharmaceuticals, Inc. "We are very pleased to name AVN316 as the lead compound for this intractable target, which we believe provides validation for our unique drug discovery platform, AvalonRx."

Using AvalonRx, the Company identified several chemical compounds series that inhibit beta-catenin function. One family of structurally distinct chemical compounds potently down-regulate the Beta-catenin pathway by reducing beta-catenin protein levels. This lead compound series (of which AVN316 is a member) decreases the beta-catenin protein levels in cancer cells and xenograft tumors, induces biomarkers of Beta-catenin pathway inhibition, and inhibits tumor growth. AVN316 was chosen from the series for its potency and tumor growth inhibition properties in animal models of human disease. Near-term activities with AVN316 include toxicology studies and large-scale manufacturing in preparation for IND submission to the FDA.


'/>"/>

Contact: Kate Gormley
kgormley@dorland.com
215-928-2720
Dorland Global Public Relations
Source:Eurekalert

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: